The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Mosunetuzumab individualized risk mitigation approach for NHL
Neurologic toxicities have resulted in restrictions in driving and other activities for patients receiving CD19-targeting therapies. Mosunetuzumab is a CD3/CD20 bispecific antibody, which may have milder neurologic toxicities than CD19-targeted therapies. Here, Catherine Diefenbach, MD, Perlmutter Cancer Center at NYU Langone Health, New York, NY, discusses the results from a systematic review of neurologic adverse events in non-Hodgkin lymophoma patients treated with this agent, where an individualized risk mitigation approach for driving allowed for a more patient-centric strategy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
